A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-02

Study Completion Date

2022-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

NCT06518122

Healthy

COMPLETED PHASE1

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

NCT05106205

Healthy

COMPLETED PHASE1

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

NCT05098262

Healthy

COMPLETED PHASE1

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

NCT05098275

Healthy

COMPLETED PHASE1

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

NCT05009368

Health, Subjective

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fixed Sequence

Period 1: RLD2202, Period 2 : RLD2203 -\> RLD2202+RLD2203

Group Type EXPERIMENTAL

RLD2202

Intervention Type DRUG

Take it once a day per period

RLD2203

Intervention Type DRUG

Take it once a day per period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RLD2202

Take it once a day per period

Intervention Type DRUG

RLD2203

Take it once a day per period

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adults in the age between 19 and 50 years old
2. Body mass index (BMI) in the range of 18 to 27 kg/m2 and weight 50kg to 90kg.
3. After fully hearing and understanding the details of this clinical trial, Subjects who have willingness to sign of informed consent before the screening.
4. Subject who are eligible from physical examination, clinical laboratory test by investigators judgment.

Exclusion Criteria

1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
2. Subjects who judged ineligible by the investigator

Minimum Eligible Age

19 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes